MONDAY, March 28 (HealthDay News) -- As the debate over medical
marijuana use continues, a new study among multiple sclerosis
patients -- who often use the drug to relieve pain and muscle
spasticity -- adds to the argument that smoking pot clouds thinking
Canadian researchers studied two groups of 25 people between the
ages of 18 and 65 with MS, an autoimmune disease that attacks the
central nervous system and can lead to paralysis, cognitive
problems, incontinence and a host of other sensory and functional
deficits. One group used marijuana heavily, while the other group
reported no marijuana use for many years.
Patients using pot performed significantly worse on cognitive
tests measuring attention, thinking speed, executive function and
visual perception of spatial relationships between objects, the
study authors said. Users were also twice as likely to be
classified as globally cognitively impaired, meaning they failed at
least two of 11 various assessments.
The study is published in the March 29 issue of
"We published a paper a few years back that said cannabis use in MS patients might be linked to delays in processing speed, but it was a very small sample," said study author Dr. Anthony Feinstein, a professor of psychiatry at the University of Toronto. "This confirms our earlier impressions that cannabis could, in fact, have some cognitive side effects . . . but I'm surprised at the breadth. We were thinking we would probably replicate our earlier findings, but it went beyond that."
Data suggests that between 36 percent and 43 percent of MS
patients have smoked pot at some time, according to the study, and
"a substantial minority" find cannabis relieves pain, insomnia,
spasticity, tremors, bladder problems and emotional distress.
Between 40 percent and 60 percent of MS patients are cognitively
impaired to begin with, Feinstein added, but study participants
using marijuana scored about one-third lower on a sensitive test of
information-processing speed than non-users.
A total of 72 percent of users reported smoking pot daily, while
24 percent reported weekly use. The average duration of marijuana
use was 26 years, the study said.
"I would stop and think very carefully about cannabis use . . . it concerns me that there's a movement that cannabis can be used as a benign drug," Feinstein said. "So I would want to look at cannabis very closely before using it. The database is still small . . . there are so many unanswered questions."
Feinstein noted that the study could not conclude that pot use
causes clouded thinking, only that the two were linked. He also
could not determine whether the slowdowns in thinking among
pot-using MS patients was any worse than might be observed among
users without MS.
Nicholas LaRocca, vice president of healthcare delivery and
policy research for the National Multiple Sclerosis Society, said
the study is "sort of a wake-up call about the potential effects of
long-term and heavy use of marijuana in people who have MS."
While the research could not be randomized because scientists
cannot assign participants to ingest a potentially harmful drug, he
said, the authors carefully matched the user and control groups and
the cognitive evaluations done on both.
Clouded thinking "is a potentially very devastating side
effect," LaRocca said. "It's a high price to pay for whatever
relief is being provided. The important thing about the study is it
gives people pretty solid information about the risks they may be
"Many people find the side effects of a given drug are worse than the symptoms," he added. "I think we're looking at a very familiar dilemma."
The National MS Society has more about